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Twenty eight both children and adults were grafted with
allogeneic umbilical cord blood cells (UCB), 15 males and 13
females. Seven patients were grafted because a non-malignant
condition and 21 for a malignant disease. The median age was 8
years (range 4 months – 72 years). Ten UCB were obtained
from Mexican cord bloods banks, ﬁve cords were from compat-
ible siblings and the remaining 13 cords were obtained from
abroad. Median time to recover  0.5  109/ L granulocytes
was 24 days (range 8 – 32 days), whereas median time to recover
 20  109/ L platelets was 26 days (range 12 – 50 days) Twelve
recipients never engrafted and recovered subsequently endoge-
nous hematopoiesis. The non-engraftment rate was signiﬁcantly
higher in patients allografted for benign conditions (71%) than
in those allografted for malignant conditions (28%). The me-
dian overall post-transplant survival (SV) was 33 months and the
73-months overall SV was 39%. The cumulative incidence of
grade II–IV acute GVHD and grade III–IV GVHD for the
entire cohort of patients were 14% and 7%, respectively. Addi-
tional studies are needed to deﬁne if non-myeloablative condi-
tioning is preferable over conventional conditioning in the case
of UCB allografting.
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CORRELATES AND OUTCOME OF ABSOLUTE LYMPHOCYTE COUNT
(ALC) ON DAY 30 POST ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) FOR TREATMENT OF AML
Saliba, R.M.1, Komanduri, K.1, Giralt, S.1, de Souza, J.1, Patah, P.A.1,
Oran, B.2, Rondon, G.1, Couriel, D.P.1, Champlin, R.1, de Lima, M.1
1University of Texas M.D. Anderson Cancer Center, Houston, TX;
2Boston University Medical Center, Boston, MA.
It has been proposed that lymphocyte recovery is associated
with transplant outcomes. We evaluated the prevalence, corre-
lates and outcome of ALC 500109/L on day 30 post SCT in
130 consecutive high-risk AML patients (pts), who received
HLA-matched unmanipulated PBSCT from a sibling donor(s-
ibling/PB, n69) or BM from a matched unrelated donor
(MUD/BM, n61) between 1996 and 2006, and who were alive
and in complete remission on day 30 post SCT. Conditioning
regimen was FM (ﬂudarabine 25-30mg/m2 for 4-5 days and
melphalan 100-180mg/m2), GVHD prophylaxis was tacrolimus
and methotrexate in 92% of pts. Results: ALC count on day 30
post SCT was signiﬁcantly lower in pts who were diagnosed
with grade II-IV acute GVHD within 30 days post SCT (n21,
median 250 109/L ) compared with grade 0-I (n109, median
650 109/L ), p0.001. Excluding pts with grade II-IV acute
GVHD, 37% of 109 patients had 500 109/L ALC on day 30.
Signiﬁcant factors associated with ALC500109/L on univar-
iate analysis included presence of circulating blasts at time of
SCT, CMV antigenemia within 30 days post SCT, and platelet
count below the median on day 30 post SCT. There was a
strong trend for lower count associated with age 57 years
(median), a higher than the median number of chemotherapy
regimens prior to SCT, and MUD/BM graft. There was no
association between ALC and gender or time to ALC
200109/L or 500109/L. These ﬁndings were consistent when
analysis was stratiﬁed by type of graft (sibling/PB and MUD/
BM) and on multivariate analysis with the exception of lower
statistical signiﬁcance for disease status at SCT. With a median
follow-up of 29 months, a landmark analysis starting at day 30
post SCT showed a signiﬁcantly higher rate of mortality and
non relapse mortality (NRM) at 3 years for pts with
ALC500109/L in recipients of a sibling/PB graft (HR OS
2.6, p 0.02 ; (HRNRM3.7, p 0.03)), but not in recipients of a
MUD/BM graft (HROS 1.2, p 0.7; HRNRM 1.3, p 0.6). There
was a trend for a higher rate of grade II-IV acute GVHD after
day 30 in the ﬁrst group (HR2.1, p 0.2) but not in the later
(HR0.6, p 0.3). There was no impact on the rate of disease
progression or chronic graft versus host disease irrespective of
the type of graft. Conclusion: In AML pts, pre- and post-
transplant factors are correlated with low ALC on day 30 post
SCT which in turn is associated with higher mortality in recip-
ients of sibling/PB transplant.
Predictors of ALC on day 30 post SCT
N
%ALC<
500109
Univariate
OR p
Multivariate
OR p
Grade II-IV aGVHD 21 76% 5.5 0.002
Grade 0-I aGVHD 109 37%
Excluding grade II-IV
aGVHD
Type of graft
sibling/PBSC 61 33%
MUD/BM 48 42% 1.5 0.3 2.1 0.1
Dose of Melphalan (mg/
m2)
100 20 25% 0.5 0.2
140/180 89 39%
Age (years)
<57 63 30%
>57 46 46% 1.9 0.09
Disease status at SCT
CR/no CR no CB* 76 29%
No CR / CB 32 53% 2.8 0.02 1.9 0.2
Lines of prior
chemotherapy lines
<median 71 31%
>median 38 47% 2 0.09
CMV antigenemia by
day 30
Positive CMV
antigenemia 20 15% 0.2 0.03 0.1 0.01
No CMV antigenemia 88 42%
Platelet count on day 30
<median 54 48% 2.7 0.015 4.2 0.01
>median 55 25%
Time to ALC 200109/L
<median 37 38% 1.1 0.9
>median 72 36%
**Time to ALC
500109/L
<median 41 32% 0.9 0.8
>median 58 31%
*CB: Circulating blasts;**evaluated in patients who recovered ALC
500109/L within 30 days
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ALLOGENEIC HEMATOPIETIC CELL TRANSPLANTATION IN MYELOFI-
BROSIS WITH MYELOID METAPLASIA – LESSONS FROM SINGLE CEN-
TER RESULTS
Baurmann, H.1, Collenbusch, F.1, Thiede, C.2, Burlakova, I.1,
Schleuning, M.1, Schwerdtfeger, R.1 1Deutsche Klinik fuer Diagnostik,
Wiesbaden, Germany; 2Carl-Gustav-Carus University of Dresden,
Dresden, Germany.
Objective: Myeloﬁbrosis with myeloid metaplasia (MMM) is a
clonal myeloproliferative disorder of later life not generally con-
sidered for allogeneic haematopoietic cell transplantation (allo-
HCT) until recently. The natural course of the disease varies
greatly but is eventually fatal in all. We present the results of 35
consecutive transplants for MMM during the last six years in our
institution. -Material andMethods: 25 males and 10 females with
primary (n29) and secondary MMM (n6) were grafted with
unmanipulated bone marrow (n21) or peripheral stem cells
(n14) from a related (n10) or unrelated (n25) donor. Median
(md) age was 51 (33-64) years. Ten patients (pts) had low, 15
intermediate and 10 high risk disease (Dupriez score 0, 1, 2). 28 pts
had a modiﬁed Charlson comorbidity index (CCI, Diaconescu et
al, Blood 104, 2004: 1550) of 0 to 2, seven one of 3 to 6. Karyo-
typing was successful in 29 pts and abnormal in 12. All but four pts
received intermediate intensity conditioning (TBI(8Gy)/Flud/Cy n
 21 or Bu(10)/Flud n  10). In all unrelated and two related
transplants rabbit ATG was added before grafting. - Results: All
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pts engrafted at a md of 22 (11-41) days. 6 pts lost complete
chimerism during follow up with proven relapse at a md of 401
days in four. At a md follow up of 23 (4-79) months probability of
overall (OS) vs eventfree survival (EFS) was 74% vs 50% for the
whole cohort. A trend towards better survival was seen in recipients
of related compared to unrelated transplants (100 vs 64 %, p0.06)
and in those with less advanced disease (90 vs 68 % in Dupriez 0 vs
12, p0.26). However the only signiﬁcant predictor for OS by
log rank test was the pretransplant CCI: 85 vs 34 % in pts with CCI
0 to 2 vs 3 to 6 (p0.01). Probability of EFS at day 480 was
signiﬁcantly less in pts with abnormal karyoptype compared to
those with no detectable anomalies (17 vs 61%, p0.01). Five pts
with decreasing chimerism received immunotherapy (3 DLI, 2
PBSC) with return to complete chimerism in three and postDLI
aplasia in one.- Conclusions: Our results support the use of
related and unrelated alloHCT as a curative treatment option in
MMM. Outcome is better in pts without disease associated and
disease independent comorbidity. For pts with abnormal karyotype
there is a considerable risk of relapse/reversal post transplant.
Especially in risk pts chimerism therefore should be monitored
closely as disease recurrence may respond to immunotherapy.
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UMBILICAL CORD BLOOD TRANSPLANTATION – REPORT OF 106 CASES
FROM A SINGLE BRAZILIAN INSTITUTION
Setubal, D.C.1, Medeiros, C.P.1, Bitencourt, M.A.1, Bonﬁm, C.M.1,
Funke, V.A.1, Zanis, J.1, Cesario, E.1, Carvalho, D.1, Nunes, E.1,
Oliveira, M.M.1, Pasquini, R.1 1BMT Center, Hospital de Clinicas da
Universidade Federal do Parana, Curitiba, Parana, Brazil.
Umbilical cord blood (UCB) has been used as a viable source of
hematopoietic stem cell for patients that need transplantation but
don’t have a suitable related donor. Between 1983 and December
2005, we performed 106 cord blood transplantations (CBT) in our
institution. Patients (pts) were treated for malignancies (n46),
Fanconi’s Anemia (FA) (n33) and other nonmalignant disorders
(n27). Median age was 6 (1-55) years. CB units were related in
14 and unrelated in 92 pts and HLA mismatch was 5/6 in 42 and
4/6 in 38 pts. Transplantation conditioning varied according to the
disease. Most pts received Cyclophosphamide with total body ir-
radiation or Bussulfan; 54 pts received antithymocyte globulin
(ATG) prior the transplantation. Graft versus host disease (GvHD)
prophylaxis consisted of Cyclosporine A (CsA)  methypred-
nisolone in 68 pts and CsA  Methotrexate in 25 pts. Median
nucleated and CD 34 cells were 6.85  107/Kg and 1.3  105/Kg
respectively. Engraftment was reached in 57% of pts. Acute GvHD
grade II-IV developed in 46% and extensive chronic GvHD in
18% of pts. The overall survival was 49% after median follow-up
of 2.1 years. Engraftment failure (28,3%) was the main cause of
death. In the Cox regression analysis ATG in the conditioning
regime (p0.002), HLA compatibility (p0.03) and infused nu-
cleated cell dose 3  10 7/Kg (p0.01) were independent pre-
dictors of neutrophil engraftment. Age  3 years (p0.01), bleed-
ing after transplantation (p0.001) and infection with identiﬁed
agent (p0.002) were signiﬁcantly associated with overall survival.
CD 34 cell count and viability, clonogenic capacity, original UCB
bank, cryopreservation time, malignant disease status and donor
type (related vs unrelated) were not associated with engraftment or
overall survival. These results conﬁrm that HLA compatibility and
the number of nucleated cells are signiﬁcantly associated with
neutrophil engraftment. We concluded that, despite a high en-
graftment failure observed, UCB is a feasible source for transplan-
tation.
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DEMONSTRATION OF A SINGLE MIHA SPECIFICITY RECOGNIZED BY
MEMORY CD8 T CELLS WHICH INDUCES RESISTANCE TO MHC-
MATCHED HEMATOPOIETIC ALLOGRAFTS
Shatry, A.M.1, Levy, R.B.1 1University of Miami, Miami, FL.
T cells that recognize transplantation antigens arise in sensitized
individuals following multiple blood transfusions or marrow trans-
plants as well as in multiparous females. Resistance to allogeneic
hematopoietic cell transplantation (HCT) in such sensitized indi-
viduals is consistent with the presence of a host memory T cell
(TM) population speciﬁc for donor cell antigens. We hypothesized
that a single donor minor histocompatibility (MiHA) epitope could
elicit antigen-speciﬁc CD8 TM capable of resisting MHC-
matched allogeneic hematopoietic cell engraftment. To address
this question, B6 mice were sensitized 2X to the H60 immuno-
dominant MiHA epitope utilizing marrow-derived dendritic cells
pulsed with the H60 (LTFNYRNL) peptide. Three weeks follow-
ing booster sensitization, circulating CD8 TM (CD44hi, Ly 6C)
were detected by tetramer staining. B6 (H2b) mice containing
CD8 H60 T cells were subsequently conditioned with 9.0 Gy
TBI and transplanted with 5 106 BALB.B (H2b) BM-TCD. One
week post-transplant, naive recipients of BALB.B (H60) or B6-
H60 congenic TCD-BM contained 10-fold higher levels of cir-
culating donor cells than the B6 dendritic cell/peptide sensitized
recipients. Donor progenitor cells were also signiﬁcantly reduced
in sensitized recipients of allogeneic TCD-BM at this time. In
contrast, two weeks post-HCT, recipients of syngeneic marrow
exhibited 10-fold greater frequency of circulating donor cells
compared to recipients of MHC-matched allogeneic marrow (
5% donor chimerism was detected). These ﬁndings demonstrate
that host T cells against a single donor MiHA determinant are
sufﬁcient to induce resistance to MHC-matched allogeneic mar-
row engraftment. These effector responses during HVG stand in
contrast to those by donor T cell responses post-HCT in which
single MiHA differences fail to induce GVHD. Finally, heterolo-
gous immunity to virus generates allo-reactive TM cells. Since
such TM repertoires could include speciﬁcity for MiHA immuno-
dominant epitopes, the presence of TM populations that can me-
diate resistance in ‘naı¨ve’ recipients may be more prevalent than
previously considered.
273
SAFETY AND EFFICACY OF HIGH-DOSE BUSULFAN BY 90-HOUR CON-
TINUOUS INFUSION IN HEMATOLOGIC MALIGNANCY PATIENTS UN-
DERGOING ALLOGENEIC STEM CELL TRANSPLANTS
Shea, T.1, Walko, C.1, Serody, J.1, Gabriel, D.1, Comeau, T.1, Rao, K.1,
Ivanova, A.1, Sharf, A.1, Krasnov, C.1, Coghill, A.1, Whitley, J.1,
Lindley, C.1 1University of North Carolina at Chapel Hill, Chapel Hill,
NC.
Busulfan is used in allotransplantation for patients with hemato-
logic malignancies. IV busulfan has recently become available and
is widely used qd or qid x 4 with ﬂudarabine in both ablative and
reduced-intensity regimens. We have previously demonstrated the
beneﬁt of using a test-dose of IV busulfan to predict the systemic
exposure of this drug (Walko, ASCO, 2005) and report here on this
approach in pts receiving a 90 hr continuous infusion of full-dose
busulfan. Methods: All pts received a 0.8 mg/kg test dose admin-
istered over 2 hours and PK sampling at times 0, 2.5, 4, 5, and 6
hours. Pts began treatment with 30 mg/m2 ﬂudarabine qd x 5 and
either 0.8 mg/kg ABW IV busulfan (18 pts) or targeted busulfan to
achieve an AUC of 4800 (6 pts) or 5700 (5 pts) umole/min/hr/day
on days –7 to –3. PK sampling was done at hours 0, 12, 16, 18, 48,
60, 72, and 89.5. All pts received tacrolimus and 0 (9 pts), 1 (10 pts),
2 (8 pts) or 3 (2 pts) doses of 30 mg of IV alemtuzamab based on
disease and donor type for prevention of GVHD prior to initiation
of chemotherapy. The initial 18 pts were studied without dose
adjustments, followed by dose escalation with targeted systemic
exposure of the busulfan and dose adjustments as needed in the last
11 pts treated. Results: 29 pts (15 MRD, 14 MUD) ages 18-55
(median 40) with high-risk AML (15), ALL (5), CML (2), IMF (2),
MDS (2), or other diseases (3) were enrolled. All pts engrafted with
a median of 14 days to an ANC 500 and 7 days to a platelet count
 20K. No regimen-related deaths were observed in the ﬁrst 100
days post-transplant. Two patients had transient grade 3 hepatitis
and two had grade 3 mucositis. There have been no cases of VOD,
pulmonary ﬁbrosis, alveolar hemorrhage or CNS toxicity. One
death at day 190 from pneumonia and one at day 191 from hem-
orrhagic cystitis and enterococcal sepsis occurred for a non-relapse
mortality rate of 7%. 14 pts have developed grade 2, one grade 3
and one grade 4 aGVHD. 6 have extensive and 2 have limited
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